Charles Schwab
MRVI icon

Charles Schwab’s Maravai LifeSciences MRVI Stock Holding History

Charles Schwab’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29M Buy
1,008,107
+14,759
+1% +$63.7K ﹤0.01% 2365
2026
Q1 		$2.81M Buy
993,348
+5,308
+0.5% +$18K ﹤0.01% 2621
2025
Q4 		$3.21M Sell
988,040
-649
-0.1% -$2.19K ﹤0.01% 2614
2025
Q3 		$2.84M Buy
988,689
+57,812
+6% +$148K ﹤0.01% 2664
2025
Q2 		$2.24M Sell
930,877
-19,870
-2% -$41.8K ﹤0.01% 2629
2025
Q1 		$2.1M Buy
950,747
+44,258
+5% +$175K ﹤0.01% 2601
2024
Q4 		$4.94M Sell
906,489
-40,087
-4% -$258K ﹤0.01% 2339
2024
Q3 		$7.87M Buy
946,576
+56,071
+6% +$485K ﹤0.01% 2153
2024
Q2 		$6.38M Buy
890,505
+248,042
+39% +$2.14M ﹤0.01% 2245
2024
Q1 		$5.57M Buy
642,463
+79,789
+14% +$540K ﹤0.01% 2243
2023
Q4 		$3.69M Sell
562,674
-47,512
-8% -$307K ﹤0.01% 2433
2023
Q3 		$6.1M Buy
610,186
+24,927
+4% +$274K ﹤0.01% 2163
2023
Q2 		$7.27M Buy
585,259
+6,804
+1% +$91.8K ﹤0.01% 2061
2023
Q1 		$8.1M Sell
578,455
-1,954
-0.3% -$28.1K ﹤0.01% 1972
2022
Q4 		$8.31M Buy
580,409
+13,602
+2% +$214K ﹤0.01% 1969
2022
Q3 		$14.5M Sell
566,807
-23,519
-4% -$590K 0.01% 1608
2022
Q2 		$16.8M Sell
590,326
-12,845
-2% -$407K 0.01% 1531
2022
Q1 		$21.3M Buy
603,171
+14,732
+3% +$494K 0.01% 1491
2021
Q4 		$24.7M Buy
588,439
+13,227
+2% +$536K 0.01% 1410
2021
Q3 		$28.2M Buy
575,212
+101,825
+22% +$4.97M 0.01% 1287
2021
Q2 		$19.8M Buy
473,387
+167,826
+55% +$6.5M 0.01% 1601
2021
Q1 		$10.9M Buy
+305,561
New +$10.1M ﹤0.01% 1914

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Charles Schwab's MRVI Position: Q2 2026 in Review

Charles Schwab increased its Maravai LifeSciences (MRVI) stake by 1.5% in Q2 2026, buying an estimated $63.7K and bringing the position to 1,008,107 shares worth $6.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

Charles Schwab first reported a position in MRVI in Q1 2021 and has held it in 22 quarters since. The position peaked at $28.2M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Charles Schwab held 1,008,107 shares of Maravai LifeSciences worth $6.29M as of Q2 2026.
  • Charles Schwab bought 14,759 Maravai LifeSciences shares in Q2 2026, an estimated $63.7K.
  • Maravai LifeSciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2365 holding.
  • Charles Schwab first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 22 quarters since.
  • Charles Schwab's Maravai LifeSciences position peaked at $28.2M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.